menu
    • menu

    Company profile for Orionis Biosciences

    NEW Drugs in Dev: 2
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orionis BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    950 Winter Street Waltham, MA 02451
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://orionisbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orionis-biosciences/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/orionisbio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    German Wound Congress

    German Wound Congress

    Not Confirmed

    envelop Contact Supplier

    German Wound Congress

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Orionis Bio Appoints Dr. Giulio Draetta Chief Strategy Officer
    Orionis Bio Appoints Dr. Giulio Draetta Chief Strategy Officer

    01 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-01/orionis-biosciences-appoints-dr-giulio-draetta-as-chief-strategy-officer

    PHARMIWEB
    01 Apr 2026
    Share Share
    Genentech Bets Again on Orionis With $2B+ in Glue Space
    Genentech Bets Again on Orionis With $2B+ in Glue Space

    22 May 2025

    // BIOSPACE

    https://www.biospace.com/business/genentech-bets-again-on-orionis-with-potential-2b-in-crowded-molecular-glue-space

    BIOSPACE
    22 May 2025
    Share Share
    ChemDiv Marks a Milestone as Orionis' Novel Immunotherapy Enters Ph I Trials
    ChemDiv Marks a Milestone as Orionis' Novel Immunotherapy Enters Ph I Trials

    03 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chemdiv-marks-a-milestone-as-orionis-biosciences-novel-immunotherapy-enters-phase-i-clinical-trials-302025515.html

    PR NEWSWIRE
    03 Jan 2024
    Share Share
    Orionis Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011
    Orionis Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011

    15 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231115320093/en

    BUSINESSWIRE
    15 Nov 2023
    Share Share
    Orionis Biosciences Announces Collaboration with Genentech
    Orionis Biosciences Announces Collaboration with Genentech

    20 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230920777229/en

    BUSINESSWIRE
    20 Sep 2023
    Share Share
    Orionis Presents Data on Interferon and IL-2 Targeted Cytokine Immunotherapies
    Orionis Presents Data on Interferon and IL-2 Targeted Cytokine Immunotherapies

    14 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221114005170/en

    BUSINESSWIRE
    14 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search